Latest Intellectual Property News

Microba Life Sciences has announced a $14.5 million capital raising, including a $2 million fully underwritten Securities Purchase Plan (SPP) and a $12.5 million Placement, aimed at fast-tracking commercialisation of its microbiome diagnostic tests in Australia and the UK.

Anagenics Limited’s licensed brand Bouf Haircare is outperforming expectations with strong early sales and promising royalty returns, signaling robust growth potential for the company’s intellectual property portfolio.

HyTerra Limited expands its Nemaha Project drilling program by adding a third well, McCoy 1, marking a shift to data-driven site selection. Early gas logs from Blythe 13-20 suggest promising hydrogen and helium presence, pending lab confirmation.

Neometals’ joint venture Reed Advanced Materials has signed a non-binding MoU with Rio Tinto to collaborate on advancing the ELi Process, a lithium hydroxide production technology promising significant cost and environmental benefits.

Neuren Pharmaceuticals has been granted a US patent for NNZ-2591 to treat Pitt Hopkins syndrome, bolstered by promising Phase 2 clinical trial results and FDA orphan drug status.

Wide Open Agriculture has achieved a breakthrough in lupin protein production, slashing energy consumption by up to 80% and halving processing time in a recent commercial-scale trial. These efficiency gains pave the way for more cost-effective, scalable manufacturing.

Civmec Limited has agreed to acquire Luerssen Australia for AUD 20 million, a move set to consolidate its position as a sovereign Australian shipbuilder and enhance its capabilities in naval vessel production.

Altair Minerals has validated its ability to detect deep copper-gold deposits at its Olympic Domain Project through a successful TEM simulation, setting the stage for a targeted drilling campaign near BHP’s Oak Dam Deposit.

Firebird Metals has reported promising lab-scale results for its lithium manganese iron phosphate cathode material, showing a significant energy density improvement over standard LFP. The company is moving towards pilot-scale production and global commercialisation.

Zoono Group Limited has announced a pro rata non-renounceable rights issue aiming to raise approximately $1.78 million at $0.035 per share. The capital raise will support shelf-life extension projects, repay related party debt, and bolster working capital.

Argenica Therapeutics has won up to $1.5 million in non-dilutive government funding to support its late-stage clinical trial of ARG-007, a promising treatment for acute ischaemic stroke.

Zoono Group Limited is raising nearly $1.8 million through a non-renounceable rights issue to fund its supermarket shelf-life extension project in Asia and reduce related party debt.